8 August 2023 - New data illustrating the health benefits of Novo Nordisk’s obesity drug Wegovy puts insurers in the increasingly uncomfortable position of justifying their refusal to pay for the new class of injectable weight-loss treatments known as GLP1 drugs. 

Shares of Novo Nordisk and its rival Eli Lilly rose on the news, which increased investor confidence that insurers will eventually be forced to cover these drugs for a wider range of people.

Read Washington Post article